JP7316261B2 - 骨髄異形成症候群の治療方法 - Google Patents

骨髄異形成症候群の治療方法 Download PDF

Info

Publication number
JP7316261B2
JP7316261B2 JP2020504178A JP2020504178A JP7316261B2 JP 7316261 B2 JP7316261 B2 JP 7316261B2 JP 2020504178 A JP2020504178 A JP 2020504178A JP 2020504178 A JP2020504178 A JP 2020504178A JP 7316261 B2 JP7316261 B2 JP 7316261B2
Authority
JP
Japan
Prior art keywords
composition
subject
imetelstat
mds
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020504178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528915A5 (enExample
JP2020528915A (ja
Inventor
アレクサンドラ リゾ，
ジャクリーン シリーロ ブッソラリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7316261(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geron Corp filed Critical Geron Corp
Publication of JP2020528915A publication Critical patent/JP2020528915A/ja
Publication of JP2020528915A5 publication Critical patent/JP2020528915A5/ja
Priority to JP2022183229A priority Critical patent/JP7654615B2/ja
Application granted granted Critical
Publication of JP7316261B2 publication Critical patent/JP7316261B2/ja
Priority to JP2023197448A priority patent/JP7654761B2/ja
Priority to JP2024197684A priority patent/JP2025013669A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020504178A 2017-07-28 2018-07-27 骨髄異形成症候群の治療方法 Active JP7316261B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022183229A JP7654615B2 (ja) 2017-07-28 2022-11-16 骨髄異形成症候群の治療方法
JP2023197448A JP7654761B2 (ja) 2017-07-28 2023-11-21 骨髄異形成症候群の治療方法
JP2024197684A JP2025013669A (ja) 2017-07-28 2024-11-12 骨髄異形成症候群の治療方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762538315P 2017-07-28 2017-07-28
US62/538,315 2017-07-28
US201762595329P 2017-12-06 2017-12-06
US62/595,329 2017-12-06
US201862685542P 2018-06-15 2018-06-15
US62/685,542 2018-06-15
PCT/US2018/044225 WO2019023667A1 (en) 2017-07-28 2018-07-27 METHODS OF TREATING MYELODYSPLASTIC SYNDROME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022183229A Division JP7654615B2 (ja) 2017-07-28 2022-11-16 骨髄異形成症候群の治療方法

Publications (3)

Publication Number Publication Date
JP2020528915A JP2020528915A (ja) 2020-10-01
JP2020528915A5 JP2020528915A5 (enExample) 2021-09-02
JP7316261B2 true JP7316261B2 (ja) 2023-07-27

Family

ID=63209674

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020504178A Active JP7316261B2 (ja) 2017-07-28 2018-07-27 骨髄異形成症候群の治療方法
JP2022183229A Active JP7654615B2 (ja) 2017-07-28 2022-11-16 骨髄異形成症候群の治療方法
JP2023197448A Active JP7654761B2 (ja) 2017-07-28 2023-11-21 骨髄異形成症候群の治療方法
JP2024197684A Pending JP2025013669A (ja) 2017-07-28 2024-11-12 骨髄異形成症候群の治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022183229A Active JP7654615B2 (ja) 2017-07-28 2022-11-16 骨髄異形成症候群の治療方法
JP2023197448A Active JP7654761B2 (ja) 2017-07-28 2023-11-21 骨髄異形成症候群の治療方法
JP2024197684A Pending JP2025013669A (ja) 2017-07-28 2024-11-12 骨髄異形成症候群の治療方法

Country Status (29)

Country Link
US (2) US12171778B2 (enExample)
EP (2) EP3658156B1 (enExample)
JP (4) JP7316261B2 (enExample)
KR (2) KR102867725B1 (enExample)
CN (2) CN110944646A (enExample)
AU (2) AU2018307983B2 (enExample)
BR (1) BR112020001749A2 (enExample)
CA (1) CA3069010A1 (enExample)
CL (2) CL2020000196A1 (enExample)
DK (1) DK3658156T3 (enExample)
ES (1) ES3073105T3 (enExample)
FI (1) FI3658156T3 (enExample)
HR (1) HRP20260793T1 (enExample)
IL (2) IL324714A (enExample)
LT (1) LT3658156T (enExample)
MA (1) MA49688B1 (enExample)
MD (1) MD3658156T2 (enExample)
MX (1) MX2025005894A (enExample)
NZ (2) NZ802277A (enExample)
PL (1) PL3658156T3 (enExample)
PT (1) PT3658156T (enExample)
RS (1) RS68210B1 (enExample)
SG (1) SG11201913984RA (enExample)
SI (1) SI3658156T1 (enExample)
SM (1) SMT202600247T1 (enExample)
TW (2) TWI906757B (enExample)
UA (1) UA127701C2 (enExample)
WO (1) WO2019023667A1 (enExample)
ZA (1) ZA202000070B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
EP3658156B1 (en) 2017-07-28 2026-03-25 Geron Corporation Telomerase inhibitor for use in treating a myelodysplastic syndrome
CN113631719A (zh) * 2018-11-29 2021-11-09 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法
CA3181682A1 (en) 2020-07-17 2022-01-20 Anil Kapur Subcutaneous telomerase inhibitor compositions and methods for using same
CN116887844A (zh) * 2021-01-18 2023-10-13 活跃生物技术有限公司 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504307A (ja) 2012-12-07 2016-02-12 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2016537423A (ja) 2013-11-06 2016-12-01 アヤルー テフェリ 血液悪性腫瘍を処置するための方法および材料

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
HK1049339B (en) 1999-09-10 2008-06-27 Geron Corporation Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use
AU2001227965A1 (en) 2000-01-21 2001-07-31 Geron Corporation 2'-arabino-fluorooligonucleotide n3'-p5'phosphoramidates: their synthesis and use
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
AU2002245717A1 (en) 2001-03-23 2002-10-08 Geron Corporation Oligonucleotide conjugates
DK3342425T3 (da) 2003-09-09 2020-03-16 Geron Corp Modificerede oligonukleotider til inhibering af telomerase
DE602004031975D1 (de) 2003-11-04 2011-05-05 Geron Corp Rna-amidate und thioamidateur rnai
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
RS61840B1 (sr) 2004-07-02 2021-06-30 Geron Corp Sinteza zaštićenih 3'-amino 5'-fosforamidit nukleozidnih monomera
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
TW200730485A (en) 2005-07-29 2007-08-16 Kalypsys Inc Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
EP4600359A2 (en) 2006-10-30 2025-08-13 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
ES2407957T3 (es) 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
US8367078B2 (en) 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
CN101220044B (zh) 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
EP2304436A1 (en) 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
EP3719139B1 (en) 2008-10-17 2022-11-30 Geron Corporation Method for identification of sensitivity of a patient to telomerase inhibition therapy
US8772264B2 (en) 2009-08-04 2014-07-08 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
ES2616055T3 (es) 2010-02-12 2017-06-09 Qiagen Marseille ASXL1 como nuevo marcador de diagnóstico de neoplasias mieloides
WO2012149339A2 (en) 2011-04-29 2012-11-01 Sequenom, Inc. Quantification of a minority nucleic acid species
US20150005250A1 (en) 2011-10-13 2015-01-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Telomerase reverse transcriptase deficiency as diagnostic marker of myelodysplastic syndrome
US20140303191A1 (en) 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
LT2925889T (lt) 2012-11-30 2018-12-27 Geron Corporation Diagnostiniai žymenys, skirti ląstelių prolifreracijos sutrikimų gydymui telomerazės inhibitoriais
US9375485B2 (en) * 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20150342982A1 (en) * 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
WO2014160071A1 (en) 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
EP3658156B1 (en) 2017-07-28 2026-03-25 Geron Corporation Telomerase inhibitor for use in treating a myelodysplastic syndrome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504307A (ja) 2012-12-07 2016-02-12 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2016537423A (ja) 2013-11-06 2016-12-01 アヤルー テフェリ 血液悪性腫瘍を処置するための方法および材料

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Blood Cancer Journal, 2016, Vol.6, #e405
Blood, 2017.12, Vol.130, No.Suppl.1, p.4256, #637
Leukemia Research, 2017（2016.11 available online), Vol.52, pp.50-57
Oncotarget, 2017.2, Vol.8, No.23, pp.37866-37874
Study NCT01731951 on Date: June 16, 2017 (v14)，ClinicalTrials.gov archive[online]，2017年6月16日，[2022年7月19日検索]，<URL: https://clinicaltrials.gov/ct2/history/NCT01731951>

Also Published As

Publication number Publication date
LT3658156T (lt) 2026-06-10
KR20250151565A (ko) 2025-10-21
EP3658156A1 (en) 2020-06-03
SG11201913984RA (en) 2020-02-27
FI3658156T3 (fi) 2026-06-18
CA3069010A1 (en) 2019-01-31
NZ802272A (en) 2026-03-27
AU2024219941A1 (en) 2024-10-10
RS68210B1 (en) 2026-07-31
ZA202000070B (en) 2025-09-25
ES3073105T3 (en) 2026-07-08
MD3658156T2 (ro) 2026-06-30
EP3658156B1 (en) 2026-03-25
JP2024015000A (ja) 2024-02-01
EP4763279A3 (en) 2026-08-19
JP2025013669A (ja) 2025-01-24
NZ802277A (en) 2026-03-27
TW201919705A (zh) 2019-06-01
UA127701C2 (uk) 2023-12-06
TW202432146A (zh) 2024-08-16
JP7654615B2 (ja) 2025-04-01
KR20200033269A (ko) 2020-03-27
EP4763279A2 (en) 2026-06-24
US12171778B2 (en) 2024-12-24
WO2019023667A1 (en) 2019-01-31
TWI879717B (zh) 2025-04-11
JP2020528915A (ja) 2020-10-01
HRP20260793T1 (hr) 2026-08-14
CL2020000196A1 (es) 2020-11-20
JP7654761B2 (ja) 2025-04-01
PT3658156T (pt) 2026-06-26
AU2018307983A1 (en) 2020-02-13
TWI906757B (zh) 2025-12-01
US20190030064A1 (en) 2019-01-31
CN121243203A (zh) 2026-01-02
IL324714A (en) 2026-01-01
NZ760873A (en) 2024-03-22
CN110944646A (zh) 2020-03-31
JP2023009229A (ja) 2023-01-19
SI3658156T1 (sl) 2026-07-31
MX2025005894A (es) 2025-06-02
KR102867725B1 (ko) 2025-10-13
MA49688B1 (fr) 2026-04-30
CL2021001096A1 (es) 2021-11-12
SMT202600247T1 (it) 2026-07-16
IL272163B1 (en) 2025-12-01
MA49688A (fr) 2020-06-03
PL3658156T3 (pl) 2026-07-27
DK3658156T3 (da) 2026-05-18
AU2024219941B2 (en) 2026-05-21
BR112020001749A2 (pt) 2020-07-21
AU2018307983B2 (en) 2024-07-18
IL272163A (en) 2020-03-31
US20260115223A1 (en) 2026-04-30

Similar Documents

Publication Publication Date Title
JP7654761B2 (ja) 骨髄異形成症候群の治療方法
KR102515378B1 (ko) 혈액 암을 위한 조합 치료법
US20250170160A1 (en) Methods of Treating Myelodysplastic Syndrome
HK40027129A (en) Methods of treating myelodysplastic syndrome
EA050072B1 (ru) Способы лечения миелодиспластического синдрома
EA045910B1 (ru) Способы лечения миелодиспластического синдрома
EA043524B1 (ru) Способы лечения миелодиспластического синдрома
HK40063245A (en) Methods of treating myelodysplastic syndrome
EA052010B1 (ru) Способы лечения миелодиспластического синдрома

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230614

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230714

R150 Certificate of patent or registration of utility model

Ref document number: 7316261

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250